Outer membrane vesicles: an attractive candidate for pertussis vaccines

References

• Sala-Farre MR, Arias-Varela C, Recasens-Recasens A, et al. Pertussis epidemic despite high levels of vaccination coverage with acellular pertussis vaccine. Enferm Infecc Microbiol Clin. 2015;33:27–31. Epub 2013/11/13.
   PubMed Web of Science ®Google Scholar
• Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Pathog Dis. 2015;73:ftv057. Epub 2015/08/09.
   PubMed Web of Science ®Google Scholar
• Bottero D, Griffith MM, Lara C, et al. Bordetella holmesii in children suspected of pertussis in Argentina. Epidemiol Infect. 2013;141:714–717. Epub 2012/08/10.
   PubMed Web of Science ®Google Scholar
• Mazengia E, Silva EA, Peppe JA, et al. Recovery of Bordetella holmesii from patients with pertussis-like symptoms: use of pulsed-field gel electrophoresis to characterize circulating strains. J Clin Microbiol. 2000;38:2330–2333. Epub 2000/06/02.
   PubMed Web of Science ®Google Scholar
• Cherry JD, Seaton BL. Patterns of Bordetella parapertussis respiratory illnesses: 2008-2010. Clin Infect Dis. 2012;54:534–537. Epub 2011/12/14.
   PubMed Web of Science ®Google Scholar
• Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;85:385–400. Epub 2010/10/14.
   PubMedGoogle Scholar
• Tan T, Dalby T, Forsyth K, et al. Pertussis across the globe: recent epidemiologic trends from 2000-2013. Pediatr Infect Dis J. 2015;34:e222-e232. Epub 2015/06/18.
   Web of Science ®Google Scholar
• Romanin V, Agustinho V, Califano G, et al. Epidemiological situation of pertussis and strategies to control it: argentina, 2002-2011. Arch Argent Pediatr. 2014;112:413–420. Epub 2014/09/06.
   PubMed Web of Science ®Google Scholar
• He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 2008;3:329–339. Epub 2008/05/29.
   PubMed Web of Science ®Google Scholar
• Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol Infect. 2014;142:672–684. Epub 2013/01/18.
   PubMed Web of Science ®Google Scholar
• Bart MJ, Harris SR, Advani A, et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. Mbio. 2014;5:e01074-14-e01074-14. Epub 2014/04/24.
   PubMed Web of Science ®Google Scholar
• Forsyth K, Plotkin S, Tan T, et al. Strategies to decrease pertussis transmission to infants. Pediatrics. 2015;135:e1475-e1482. Epub 2015/05/13.
   PubMed Web of Science ®Google Scholar
• Gentile A, Bakir J, Firpo V, et al. Delayed vaccine schedule and missed opportunities for vaccination in children up to 24 months. A multicenter study. Arch Argent Pediatr. 2011;109:219–225. Epub 2011/06/11.
   PubMed Web of Science ®Google Scholar
• Pesco P, Bergero P, Fabricius G, et al. Mathematical modeling of delayed pertussis vaccination in infants. Vaccine. 2015;33:5475–5480. Epub 2015/07/19.
   PubMed Web of Science ®Google Scholar
• McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015;135:331–343. Epub 2015/01/07.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367:1012–1019. Epub 2012/09/14.
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24:S58–61. Epub 2005/05/07.
   PubMedGoogle Scholar
• Desauziers E, Hessel L, Decker MD, et al. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2004;22:2681-4; author reply 2685. Epub 2004/07/13.
   PubMed Web of Science ®Google Scholar
• Klein NP. Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother. 2014;10:2684–2690. Epub 2014/12/09.
   PubMed Web of Science ®Google Scholar
• Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J. 1987;6:364–371. Epub 1987/04/01.
   PubMed Web of Science ®Google Scholar
• Sato H, Sato Y. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis. Dev Biol Stand. 1985;61:461–467. Epub 1985/01/01.
   PubMedGoogle Scholar
• Edwards KM, Karzon DT. Pertussis vaccines. Pediatr Clin North Am. 1990;37:549–566. Epub 1990/06/01.
   PubMed Web of Science ®Google Scholar
• Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis. 2014;209:978–981. Epub 2014/03/15.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131:e1716–e1722. Epub 2013/05/22.
   PubMed Web of Science ®Google Scholar
• Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012;54:1730–1735. Epub 2012/03/17.
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Ware RS, Grimwood K, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA: Journal Am Med Assoc. 2012;308:454–456. Epub 2012/08/02.
   PubMed Web of Science ®Google Scholar
• Witt MA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013;56:1248–1254. Epub 2013/03/15.
   PubMed Web of Science ®Google Scholar
• Mills KH, Ross PJ, Allen AC, et al. Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol. 2014;22:49–52. Epub 2014/02/04.
   PubMed Web of Science ®Google Scholar
• Meeting of the strategic advisory group of experts on immunization, April 2015: conclusions and recommendations. Wkly Epidemiol Rec. 2015;90:261–278. Epub 2015/06/02.
   PubMedGoogle Scholar
• Allen AC, Mills KH. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert Rev Vaccines. 2014;13:1253–1264. Epub 2014/07/16.
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Debrie AS, Raze D, et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. Plos Pathog. 2006;2:e65. Epub 2006/07/15.
   PubMed Web of Science ®Google Scholar
• Dias WO, van der Ark AA, Sakauchi MA, et al. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum Vaccin Immunother. 2013;9:339–348. Epub 2013/01/08.
   PubMed Web of Science ®Google Scholar
• Hansson M, Nygren PA, Stahl S. Design and production of recombinant subunit vaccines. Biotechnol Appl Biochem. 2000;32(Pt 2):95–107. Epub 2000/09/26.
   PubMed Web of Science ®Google Scholar
• Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6:797–808. Epub 2007/10/13.
   PubMed Web of Science ®Google Scholar
• Harandi AM, Davies G, Olesen OF. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines. 2009;8:293–298. Epub 2009/03/03.
   PubMed Web of Science ®Google Scholar
• Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54–S65. Epub 2010/02/11.
   PubMed Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–B12. Epub 2009/06/02.
   PubMed Web of Science ®Google Scholar
• Zariri A, Beskers J, van de Waterbeemd B, et al. Meningococcal outer membrane vesicle composition-dependent activation of the innate immune response. Infect Immun. 2016;84:3024–3033. Epub 2016/08/03.
   PubMed Web of Science ®Google Scholar
• Unal CM, Schaar V, Riesbeck K. Bacterial outer membrane vesicles in disease and preventive medicine. Semin Immunopathol. 2011;33:395–408. Epub 2010/12/15.
   PubMed Web of Science ®Google Scholar
• Roberts R, Moreno G, Bottero D, et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine. 2008;26:4639–4646. Epub 2008/07/22.
   PubMed Web of Science ®Google Scholar
• Asensio CJ, Gaillard ME, Moreno G, et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine. 2011;29:1649–1656. Epub 2011/01/08.
   PubMed Web of Science ®Google Scholar
• Gaillard ME, Bottero D, Errea A, et al. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine. 2014;32:931–937. Epub 2014/01/09.
   PubMed Web of Science ®Google Scholar
• Stoddard MB, Pinto V, Keiser PB, et al. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. CVI. 2010;17:98–107. Epub 2009/11/20.
   Web of Science ®Google Scholar
• Bottero D, Gaillard ME, Zurita E, et al. Characterization of the immune response induced by pertussis OMVs-based vaccine. Vaccine. 2016;34:3303–3309. Epub 2016/05/07.
   PubMed Web of Science ®Google Scholar
• Ormazabal M, Bartel E, Gaillard ME, et al. Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles. Vaccine. 2014;32:6084–6090. Epub 2014/09/23.
   PubMed Web of Science ®Google Scholar
• Martin SW, Pawloski L, Williams M, et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis. 2015;60:223–227. Epub 2014/10/11.
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012;8:174–183. Epub 2012/03/20.
   PubMed Web of Science ®Google Scholar
• Bottero D, Gaillard ME, Errea A, et al. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection. Vaccine. 2013;31:5262–5268. Epub 2013/09/10.
   PubMed Web of Science ®Google Scholar
• Benne N, van Duijn J, Kuiper J, et al. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines. J Control Release. 2016;234:124–134. Epub 2016/05/26.
   PubMed Web of Science ®Google Scholar